Background: IgA nephropathy (IgAN) is the most frequent glomerulonephritis worldwide. Different therapeutic approaches have been tested against IgAN. The present study was designed to explore the renoprotective potential of low-dose mammalian target of rapamycin (mTOR) inhibitor rapamycin in an IgAN rat model and the possible mechanism of action. Methods: After establishing an IgAN model, the rats were randomly divided into four groups: control, control with rapamycin treatment, IgAN model, and IgAN model with rapamycin treatment. Coomassie Brilliant Blue was utilized to measure 24-hour urinary protein levels. Hepatic and renal function was determined with an autoanalyzer. Proliferation was assayed via 5-bromo-2′-deoxyuridine incorporation. Real-time PCR and immunohistochemistry were utilized to detect the expression of α-SMA, collagen I, collagen III, TGF-β1 and platelet-derived growth factor. Western blotting and immunohistochemistry were performed to determine p-S6 protein levels. Results: Low-dose mTOR inhibitor rapamycin prevented an additional increase in proteinuria and protected kidney function in a model of IgAN. Rapamycin directly or indirectly interfered with multiple key pathways in the progression of IgAN to end-stage renal disease: (1) reduced the deposition of IgA and inhibited cell proliferation; (2) decreased the expression of fibrosis markers α-SMA and type III collagen, and (3) downregulated the expression of the profibrotic growth factors platelet-derived growth factor and TGF-β1. The expression of p-S6 was significantly elevated in IgAN rats. Conclusions: The mTOR pathway was activated in IgAN rats and the early application of low-dose mTOR inhibitor rapamycin may slow the renal injury of IgAN in rats.

Keywords:
mTOR, Mammalian target of rapamycin, Rapamycin, IgA nephropathy
1.
Donadio JV, Grande JP: IgA nephropathy. N Engl J Med 2002;347:738-748.
2.
Floege J, Feehally J: IgA nephropathy: recent developments. J Am Soc Nephrol 2000;11:2395-2403.
3.
Praga M, et al: Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 2003;14:1578-1583.
4.
Floege J, Eitner F: Combined immunosuppression in high-risk patients with IgA nephropathy? J Am Soc Nephrol 2010;21:1604-1606.
5.
Coppo R, Pozzi C, Amore A: The role of steroids in the treatment of IgA nephropathy (in Italian). G Ital Nefrol 2009;26:421-441.
6.
Buemi M, et al: Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy. Clin Pharmacol Ther 2000;67:427-431.
7.
Hogg RJ, et al: Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006;1:467-474.
8.
Lai KN: Pathogenesis of IgA nephropathy. Nat Rev Nephrol 2012;8:275-283.
9.
Brunskill NJ: Rapamycin: a new string to the antiproteinuric bow? J Am Soc Nephrol 2005;16:1878-1879.
10.
Liu Y: Rapamycin and chronic kidney disease: beyond the inhibition of inflammation. Kidney Int 2006;69:1925-1927.
11.
Sarbassov DD, Ali SM, Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005;17:596-603.
12.
Lloberas N, et al: Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006;17:1395-1404.
13.
Tao Y, et al: Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005;16:46-51.
14.
Bonegio RG, et al: Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy. J Am Soc Nephrol 2005;16:2063-2072.
15.
Chen JK, et al: Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy. J Am Soc Nephrol 2005;16:1384-1391.
16.
Hochegger K, et al: Differential effects of rapamycin in anti-GBM glomerulonephritis. J Am Soc Nephrol 2008;19:1520-1529.
17.
Lock HR, Sacks SH, Robson MG: Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production. Am J Physiol Renal Physiol 2007;292:F76-F81.
18.
Krämer S, et al: Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat. Am J Physiol Renal Physiol 2008;294:F440-F449.
19.
Cruzado JM, et al: Low-dose sirolimus combined with angiotensin-converting enzyme inhibitor and statin stabilizes renal function and reduces glomerular proliferation in poor prognosis IgA nephropathy. Nephrol Dial Transplant 2011;26:3596-3602.
20.
Lai KN, et al: Additive effect of PPAR-α agonist and ARB in treatment of experimental IgA nephropathy. Pediatr Nephrol 2011;26:257-266.
21.
Katzir Z, et al: Effect of atorvastatin on IgA nephropathy in the rat. Clin Nephrol 2013;79:214-220.
22.
Huang H, et al: Tonsillar CD4+CD25+ regulatory T cells from IgA nephropathy patients have decreased immunosuppressive activity in experimental IgA nephropathy rats. Am J Nephrol 2013;37:472-480.
23.
Zhong Q, et al: The study of Chinese medicinal herbal formula Shen San Fang in the treatment of experimental IgA nephropathy. Am J Chin Med 2005;33:613-626.
24.
Chan W, et al: Alpha-tocopherol reduces proteinuria, oxidative stress, and expression of transforming growth factor-β1 in IgA nephropathy in the rat. Mol Genet Metab 1998;63:224-229.
25.
Trachtman H, et al: Vitamin E ameliorates renal injury in an experimental model of immunoglobulin A nephropathy. Pediatr Res 1996;40:620-626.
26.
Liboska R, et al: Most anti-BrdU antibodies react with 2′-deoxy-5-ethynyluridine - the method for the effective suppression of this cross-reactivity. PLoS One 2012;7:e51679.
27.
Segarra A: Progress in understanding the pathogenesis of IgA nephropathy: new perspectives for the near future? Nefrologia 2010;30:501-507.
28.
Stoycheff N, et al: Early change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset. Nephrol Dial Transplant 2011;26:848-857.
29.
Diekmann F, et al: Mammalian target of rapamycin inhibition halts the progression of proteinuria in a rat model of reduced renal mass. J Am Soc Nephrol 2007;18:2653-2660.
30.
Schlondorff D, Banas B: The mesangial cell revisited: no cell is an island. J Am Soc Nephrol 2009;20:1179-1187.
31.
Makino H: Glomerular extracellular matrix in glomerulosclerosis by molecular biology. Nihon Rinsho 1992;50:3038-3045.
32.
Imai E, et al: Introduction of a foreign gene into the kidney in vivo: development of glomerulosclerosis by the transfection of genes for PDGF and TGF-β. Contrib Nephrol. Basel, Karger, 1994, vol 107, pp 205-215.
33.
Mima A, et al: Activation of Src mediates PDGF-induced Smad1 phosphorylation and contributes to the progression of glomerulosclerosis in glomerulonephritis. PLoS One 2011;6:e17929.
34.
Chihara Y, et al: Roles of TGF-β1 and apoptosis in the progression of glomerulosclerosis in human IgA nephropathy. Clin Nephrol 2006;65:385-392.
35.
Groth CG, et al: Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999;67:1036-1042.
36.
Brattstrom C, et al: Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998;65:1272-1274.
37.
Kahan BD, Napoli KL: Role of therapeutic drug monitoring of rapamycin. Transplant Proc 1998;30:2189-2191.
38.
Inoki K, et al: mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest 2011;121:2181-2196.
39.
Tumlin JA, et al: A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2006;1:109-116.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.